Detalhe da pesquisa
1.
Reducing affinity as a strategy to boost immunomodulatory antibody agonism.
Nature
; 614(7948): 539-547, 2023 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-36725933
2.
Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.
Immunity
; 49(5): 958-970.e7, 2018 11 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-30446386
3.
Development and Characterization of Monoclonal Antibodies Specific for Mouse and Human Fcγ Receptors.
J Immunol
; 195(11): 5503-16, 2015 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26512139
4.
Immunotherapy targeting inhibitory Fcγ receptor IIB (CD32b) in the mouse is limited by monoclonal antibody consumption and receptor internalization.
J Immunol
; 191(8): 4130-40, 2013 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-24026082
5.
Development and characterisation of monoclonal antibodies specific for the murine inhibitory FcγRIIB (CD32B).
Eur J Immunol
; 42(8): 2109-20, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22760702
6.
Fc-null anti-PD-1 monoclonal antibodies deliver optimal checkpoint blockade in diverse immune environments.
J Immunother Cancer
; 10(1)2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35017153
7.
Agonistic CD27 antibody potency is determined by epitope-dependent receptor clustering augmented through Fc-engineering.
Commun Biol
; 5(1): 229, 2022 03 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-35288635
8.
Hinge disulfides in human IgG2 CD40 antibodies modulate receptor signaling by regulation of conformation and flexibility.
Sci Immunol
; 7(73): eabm3723, 2022 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35857577
9.
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.
Cell Rep
; 40(3): 111099, 2022 07 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-35858562
10.
TNF receptor agonists induce distinct receptor clusters to mediate differential agonistic activity.
Commun Biol
; 4(1): 772, 2021 06 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-34162985
11.
Isotype Switching Converts Anti-CD40 Antagonism to Agonism to Elicit Potent Antitumor Activity.
Cancer Cell
; 37(6): 850-866.e7, 2020 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32442402
12.
PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8+ T-Cell-Driven Antitumor Immunity.
Clin Cancer Res
; 24(10): 2383-2394, 2018 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514845
13.
Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.
Sci Rep
; 8(1): 2278, 2018 02 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-29396470
14.
Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.
Cancer Cell
; 33(4): 664-675.e4, 2018 04 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29576376
15.
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodies.
Cancer Cell
; 27(1): 138-48, 2015 Jan 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-25500122